logo-loader
Micro Focus

Micro Focus jumps as says new US$40mln licensing deal will help bolster first-half revenue

The FTSE 100-listed firm said that the earlier than expected signing of a new contract meant its first-half revenue would be better than the guidance it gave of minus 9% to minus 12% on a constant currency basis

Micro Focus office
Stripping out the impact of the new contract, Micro Focus said its underlying revenue was still towards the “better end” of that guidance range

Micro Focus International PLC (LON:MCRO) shares jumped higher on Wednesday after the software group, which issued a profit warning back in March, said a new US$40mln licensing deal will help bolster its first-half revenue.

In a pre-close season trading update, the FTSE 100-listed firm said that the earlier than expected signing of a new contract meant its first-half revenue would be better than the guidance it gave of minus 9% to minus 12% on a constant currency basis.

READ: Micro Focus spikes higher on report activist investor Elliott has built up stake

Stripping out the impact of the new contract, Micro Focus said its underlying revenue was still towards the “better end” of that guidance range For the full-year, the company reiterated its revenue and margin guidance.

Back in March, Micro Focus announced the departure of its chief executive as it cut its revenue outlook due to problems integrating assets acquired from Hewlett Packard Enterprise last year.

New chief executive Stephen Murdoch said in the latest statement that the group is “making encouraging progress on improving both the discipline and speed of execution within the business."

Micro Focus shares dropped 46% on the day of its profit warning in March but have rallied by over 25% since then.

In early morning trading. Micro Focus shares were up 8.5% to 1,377p.

 -- Adds share price --

Quick facts: Micro Focus

Price: £15.98

Market: LSE
Market Cap: £5.44 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Scancell back in the clinic with a phase II trial of its...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment. The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s...

14 hours, 11 minutes ago

RNS

Transaction in Own Shares

20 hours, 43 minutes ago

Transaction in Own Shares

3 days, 20 hours ago

Transaction in Own Shares

4 days, 20 hours ago

Transaction in Own Shares

5 days, 20 hours ago

Transaction in Own Shares

6 days, 20 hours ago

Transaction in Own Shares

1 week, 1 day ago

Transaction in Own Shares

1 week, 4 days ago

Transaction in Own Shares

1 week, 5 days ago

2 min read